Invest in MJ Blog

Invest In MJ is a multi-author and community member blog. Read the latest blogs about investment ideas in the marijuana and cannabis industry.

  • Home
    Home This is where you can find all the blog posts throughout the site.
  • Categories
    Categories Displays a list of categories from this blog.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Bloggers
    Bloggers Search for your favorite blogger from this site.
  • Team Blogs
    Team Blogs Find your favorite team blogs here.
  • Archives
    Archives Contains a list of blog posts that were created previously.
  • Login
    Login Login form
Subscribe to this list via RSS Blog posts tagged in Cannabis Company

COSTA MESA, CA--(Marketwired - Mar 22, 2017) - NEMUS Bioscience, Inc. (OTCQB : NMUS ) and the company's discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA. 

In vitro studies demonstrated that when using unique strategic cannabinoid-based cocktails, fractional-inhibitory concentration (FIC) levels demonstrating synergy between mixtures of individual cannabinoid-based components ranged from 0.06 to 0.28. FIC findings below 0.5 indicate significant killing potential of the mixture.

"This work highlights the importance of Nemus' relationship with the University which has significant experience and intellectual capital related to cannabinoid chemistry and physiology, dating back to 1968," stated Brian Murphy, M.D., C.E.O. and Chief Medical Officer of Nemus. "These unique botanically derived components establish an anti-infective platform which could potentially be expanded into other types of bacteria, as well as viruses, and fungi."

Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research (NCNPR) at the University of Mississippi commented: "The University, in conjunction with Nemus, is looking to expand the anti-infective capabilities of this series of compounds. Historically, many types of anti-infective compounds are derived from plants so to have a series of cannabinoid-related compounds exhibit activity against this dangerous pathogen is in keeping with prior efforts of drug development. I believe that these compounds, in addition to the bacterial killing capability, could also offer benefits associated with anti-inflammatory and anti-fibrotic properties that could enhance healing, especially against an organism associated with skin and soft tissue infections."

"This anti-infective platform will constitute the NB3000 series of Nemus molecules and formulations. Recently, the World Health Organization (WHO) placed MRSA on their list as one of the top six organisms that pose a global public health threat. While there are a number of compounds in the development pipeline against MRSA, we believe that this family of drug candidates could possess an excellent safety profile in addition to efficacy in neutralizing this bacterium," stated Dr. Murphy. "Nemus will work with Dr. Elsohly, the University lead researcher on this project, to have this data submitted to a future scientific meeting and anticipates performing further testing against a variety of other bacterial species. Commercially, the company looks to actively pursue partnering opportunities for these candidate molecules."

FORWARD LOOKING STATEMENT

This press release contains forward-looking statements, including statements about the studies relating to and the potential benefits of the NB3000 series of drug candidates as well as the timing of our near term, intermediate term and long term goals. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "goal," "focus," "aims," "expects," "plans," "believes," "can," "could," "challenge," "predictable," "will," or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of NEMUS's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, NEMUS disclaims any intent or obligation to update these forward-looking statements.

Rate this blog entry:
0

Marijuana Stocks haven’t risen much after the U.S. Elections and the win by Donald Trump.
The five states have voted on full legalization, while four other states could legalize medical marijuana.
Here are the results: California, Massachusetts, Maine and Nevada have voted to legalize recreational marijuana in their states, while Arizona rejected its measure.  Four other states — Arkansas, Florida, Montana and North Dakota — passed ballot measures legalizing medical marijuana.    A recent poll suggests a majority of Americans support the legalization of Marijuana, now with these new states voting in favor of marijuana reform and legalization we could be on the way toward a majority of citizens living in a state that allows for some form of legal marijuana.

Rate this blog entry:
0

Canadian Market Overview

The Canadian cannabis sector continues to be blazing hot over the last year, especially in the last 2 months.  The following chart shows the performance of the Canadian marijuana sector in general, the Marijuana Index Canada  contains a list of 10 publicly traded Canadian companies in the space, their stock prices and market caps.  Just looking at this chart, there has been a parabolic rise in share price since May of this year.  Most parabolic rises like this are usually followed by a correction and then a basing period before any further advances can be made.  The chart does show a clear break out and passed overhead resistance, this means we are in a new bull market for cannabis stocks in Canada.  We will provide an update on the American cannabis sector shortly.

Rate this blog entry:
0
Tweed Acquires MedCannAccess and Opens Dispensaries in Ontario

Tweed, one of Canada's first medical cannabis producers, recently renamed Canopy Growth Corporation, has opened a dispensary in Guelph. The storefront now known as Better by Tweed, opened Oct. 15 and is the town’s first dispensary.

In September, Tweed purchased MedCannAccess a company focused on helping new medical marijuana patients and acquired the group’s three community access centres in Guelph, Hamilton and the Greater Toronto Area. The Hamilton location opened earlier in the week and Better by Tweed will soon expand with the Etobicoke Better Centre. 

The MedCannAccess locations had helped cannabis patients register with a licensed producer.

The Better by Tweed operation will provide patients with information packages to bring to their doctors to fill out and then return to the store where they can place orders for cannabis from Tweed’s production facilities in Smiths Falls, Toronto and Niagara-on-the-Lake.

“There will always be a market for medical marijuana, and, if the time comes, we’re well equipped for recreational use as well,” said Tweed president Mark Zekulin.

Rate this blog entry:
0
MassRoots Files Application For Listing To The NASDAQ Capital Market

MassRoots, Inc. (MSRT), one of the largest and fastest growing social networks for cannabis consumers, is pleased to announce it has filed an application to become one of the first cannabis technology companies listed on the NASDAQ Capital Market. Last year, MassRoots was one of the first cannabis-related companies to go public through a Registration Statement on Form S-1, as opposed to a reverse-merger.

MassRoots has demonstrated tremendous growth in recent quarters, more than doubling its userbase since the beginning of 2015 to a half million users. The Company recently started monetizing its digital properties and is expecting to rapidly scale its revenues over the next several quarters. Sitting at the intersection of cannabis and mobile technology, MassRoots offers a direct play on the regulated marijuana industry without ever touching the plant itself.

“Uplisting to the NASDAQ Capital Market would be a significant milestone not just for MassRoots, but the cannabis industry as a whole,” stated MassRoots Chief Executive Officer Isaac Dietrich. “We believe that uplisting to a national exchange like the NASDAQ would enable MassRoots to attract a broader range of institutional investors, increase share liquidity and help shift the paradigm about investing in the regulated marijuana market.”

Rate this blog entry:
0

Select Your Language

enzh-CNnlfrdehies

Crowd Funding Campaigns

Featured Listing